Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayOct 29, 2019 9:40 am

Ur-Energy (NYSE: URG) Starts Presentation at Dawson James Small Cap Growth Conference

Ur-Energy (NYSE: URG) engages in uranium mining and recovery operations, with activities including acquisition, exploration, development and operation of uranium mineral properties in the U.S. The company operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming. Ur-Energy has produced, packaged and shipped more than 2 million pounds from Lost Creek since the commencement of operations. The company's newest project, Shirley Basin, is one of the Pathfinder Mines assets acquired in 2013. Baseline studies necessary for permitting and licensing of the project are complete, the WDEQ application for permit to mine has been submitted, and work on other permits…

Continue Reading

TuesdayOct 29, 2019 9:15 am

Interpace Diagnostics Group Inc. (NASDAQ: IDXG) Starts Presentation at Dawson James Small Cap Growth Conference

Interpace Diagnostics Group (NASDAQ: IDXG) is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. A leader in enabling personalized medicine, Interspace offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The company's molecular diagnostic tests deliver cutting-edge genetic and mutational analysis that help risk-stratify patient samples for thyroid, pancreatic, lung and other cancers to better inform treatment decisions. Supported by rigorous science, the company's molecular diagnostic tests allow healthcare providers the ability to avoid unnecessary surgeries and better assess the risk…

Continue Reading

TuesdayOct 29, 2019 9:15 am

Can-Fite Biopharma Ltd. (NYSE: CANF) Starts Presentation at Dawson James Small Cap Growth Conference

Can-Fite BioPharma (NYSE: CANF) is an advanced clinical-stage drug development company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancers. Can-Fite's technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells. The company has several drugs in various stages of research and development. Its lead drug candidate, Piclidenoson, is currently in Phase III trials for…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000